Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Myeloperoxidase genotypes and enhanced efficacy of chemotherapy for early-stage breast cancer in SWOG-8897.
Ambrosone CB, Barlow WE, Reynolds W, Livingston RB, Yeh IT, Choi JY, Davis W, Rae JM, Tang L, Hutchins LR, Ravdin PM, Martino S, Osborne CK, Lyss AP, Hayes DF, Albain KS. Ambrosone CB, et al. Among authors: lyss ap. J Clin Oncol. 2009 Oct 20;27(30):4973-9. doi: 10.1200/JCO.2009.21.8669. Epub 2009 Sep 14. J Clin Oncol. 2009. PMID: 19752340 Free PMC article. Clinical Trial.
Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102.
Hutchins LF, Green SJ, Ravdin PM, Lew D, Martino S, Abeloff M, Lyss AP, Allred C, Rivkin SE, Osborne CK. Hutchins LF, et al. Among authors: lyss ap. J Clin Oncol. 2005 Nov 20;23(33):8313-21. doi: 10.1200/JCO.2005.08.071. J Clin Oncol. 2005. PMID: 16293862 Clinical Trial.
Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel.
Liu MC, Demetri GD, Berry DA, Norton L, Broadwater G, Robert NJ, Duggan D, Hayes DF, Henderson IC, Lyss A, Hopkins J, Kaufman PA, Marcom PK, Younger J, Lin N, Tkaczuk K, Winer EP, Hudis CA; Cancer and Leukemia Group B. Liu MC, et al. Cancer Treat Rev. 2008 May;34(3):223-30. doi: 10.1016/j.ctrv.2007.11.004. Epub 2008 Jan 30. Cancer Treat Rev. 2008. PMID: 18234424 Free PMC article. Clinical Trial.
Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer.
Fidias PM, Dakhil SR, Lyss AP, Loesch DM, Waterhouse DM, Bromund JL, Chen R, Hristova-Kazmierski M, Treat J, Obasaju CK, Marciniak M, Gill J, Schiller JH. Fidias PM, et al. Among authors: lyss ap. J Clin Oncol. 2009 Feb 1;27(4):591-8. doi: 10.1200/JCO.2008.17.1405. Epub 2008 Dec 15. J Clin Oncol. 2009. PMID: 19075278 Clinical Trial.
Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial.
Choi JY, Barlow WE, Albain KS, Hong CC, Blanco JG, Livingston RB, Davis W, Rae JM, Yeh IT, Hutchins LF, Ravdin PM, Martino S, Lyss AP, Osborne CK, Abeloff MD, Hayes DF, Ambrosone CB. Choi JY, et al. Among authors: lyss ap. Clin Cancer Res. 2009 Aug 15;15(16):5258-66. doi: 10.1158/1078-0432.CCR-09-0685. Epub 2009 Aug 11. Clin Cancer Res. 2009. PMID: 19671875 Free PMC article. Clinical Trial.
Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer.
Yao S, Barlow WE, Albain KS, Choi JY, Zhao H, Livingston RB, Davis W, Rae JM, Yeh IT, Hutchins LF, Ravdin PM, Martino S, Lyss AP, Osborne CK, Abeloff MD, Hortobagyi GN, Hayes DF, Ambrosone CB. Yao S, et al. Among authors: lyss ap. Breast Cancer Res Treat. 2010 Nov;124(2):433-9. doi: 10.1007/s10549-010-0840-0. Epub 2010 Mar 23. Breast Cancer Res Treat. 2010. PMID: 20309628 Free PMC article. Clinical Trial.
Gene polymorphisms in cyclophosphamide metabolism pathway,treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancer.
Yao S, Barlow WE, Albain KS, Choi JY, Zhao H, Livingston RB, Davis W, Rae JM, Yeh IT, Hutchins LF, Ravdin PM, Martino S, Lyss AP, Osborne CK, Abeloff M, Hortobagyi GN, Hayes DF, Ambrosone CB. Yao S, et al. Among authors: lyss ap. Clin Cancer Res. 2010 Dec 15;16(24):6169-76. doi: 10.1158/1078-0432.CCR-10-0281. Clin Cancer Res. 2010. PMID: 21169260 Free PMC article. Clinical Trial.
Phase 2 trial of paclitaxel polyglumex with capecitabine for metastatic breast cancer.
Northfelt DW, Allred JB, Liu H, Hobday TJ, Rodacker MW, Lyss AP, Fitch TR, Perez EA; North Central Cancer Treatment Group. Northfelt DW, et al. Among authors: lyss ap. Am J Clin Oncol. 2014 Apr;37(2):167-71. doi: 10.1097/COC.0b013e31826e0550. Am J Clin Oncol. 2014. PMID: 23211220 Free PMC article. Clinical Trial.
67 results